The HSP70 modulator MAL3-101 inhibits Merkel cell carcinoma

54Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

Abstract

Merkel Cell Carcinoma (MCC) is a rare and highly aggressive neuroendocrine skin cancer for which no effective treatment is available. MCC represents a human cancer with the best experimental evidence for a causal role of a polyoma virus. Large T antigens (LTA) encoded by polyoma viruses are oncoproteins, which are thought to require support of cellular heat shock protein 70 (HSP70) to exert their transforming activity. Here we evaluated the capability of MAL3-101, a synthetic HSP70 inhibitor, to limit proliferation and survival of various MCC cell lines. Remarkably, MAL3-101 treatment resulted in considerable apoptosis in 5 out of 7 MCC cell lines. While this effect was not associated with the viral status of the MCC cells, quantitative mRNA expression analysis of the known HSP70 isoforms revealed a significant correlation between MAL3-101 sensitivity and HSC70 expression, the most prominent isoform in all cell lines. Moreover, MAL3-101 also exhibited in vivo antitumor activity in an MCC xenograft model suggesting that this substance or related compounds are potential therapeutics for the treatment of MCC in the future. © 2014 Adam et al.

Cite

CITATION STYLE

APA

Adam, C., Baeurle, A., Brodsky, J. L., Wipf, P., Schrama, D., Becker, J. C., & Houben, R. (2014). The HSP70 modulator MAL3-101 inhibits Merkel cell carcinoma. PLoS ONE, 9(4). https://doi.org/10.1371/journal.pone.0092041

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free